A Phase 2/3 interventional study of Baricitinib and Placebo in Alopecia Areata, sponsored by Eli Lilly and Company. Completed at 75 sites in 5 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Eli Lilly and Company · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.
Among the 98 studies in Alopecia Areata with a site in United States, this one is the 4th largest by enrollment of the 84 interventional ones that give a count, is one of 6 that started in 2018, is one of 4 in phase 2/3, and was the 37th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:
AbbVie · Sites in United States, Australia, Japan and 1 more country
Ages 6–17
Pfizer · Sites in United States, Canada, China and 2 more countries
Ages 12+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18–60
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
Almirall, S.A. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 48 · Phase 3 16 · Phase 4 8
First in 1997; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 784 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 46 across the 84 interventional studies, 2,300 across the 14 observational. Of the 60 that completed or were terminated, 42 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 98 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 3 studies filed under Alopecia Areata — fewer than ten, so there is no comparison to draw.
10 of the studies in Alopecia Areata with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT03898479Phase 3Sun Pharmaceutical Industries, Inc.Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2027-05 |
| NCT06826196Aldena TherapeuticsA Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata | 2026-11 |
| NCT07821216PfizerReal-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data | 2026-11-20 |
| NCT06602232Dren BioA Study of DR-01 in Subjects With Alopecia Areata and Vitiligo | 2027-05 |
Add all 10 to your calendar (.ics) → With an account.
Among the 98 studies in Alopecia Areata with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants in the US will enroll in the open-label addenda.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have severe or very severe AA, as determined by all of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received three placebo tablets administered orally once daily (QD). Rescue therapy with Baricitinib 2 mg or 4 mg was provided to participants who failed to achieve Severity of Alopecia Tool (SALT) ≤20 (less than or equal to 20) during the study period.
Drug: Baricitinib · Drug: Placebo
Participants received one 1 mg baricitinib tablet administered orally QD and two placebo tablets administered orally QD to maintain the blind through Week 12. Following the decision point at Week 12, participants were transitioned to receive one 4 mg baricitinib tablet administered orally QD and two placebo tablets administered orally QD to maintain the blind, and continued treatment through Week 200.
Drug: Baricitinib
Participants received one 2 mg Baricitinib tablet administered orally QD, and two placebo tablets administered orally QD to maintain the blind.
Drug: Baricitinib
Participants received one 4 mg Baricitinib tablet administered orally, QD and two placebo tablets QD administered orally to maintain the blind.
Drug: Baricitinib
Participants received two placebo tablets administered orally QD. Rescue therapy with Baricitinib 2 mg or 4 mg was provided to participants who failed to achieve SALT≤20 during this treatment period.
Drug: Baricitinib · Drug: Placebo
Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.
Drug: Baricitinib
Participants received one 4 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.
Drug: Baricitinib
Participants who received two placebo tablets administered orally QD in Period 1 continue to receive the same placebo in Period 2.
Drug: Placebo
Participants who received Placebo at Period 1 switched to receive 2 mg Baricitinib dose administered orally QD in Period 2.
Drug: Baricitinib
Participants who received Placebo at Period 1 switched to receive 4 mg Baricitinib dose administered orally QD in Period 2.
Drug: Baricitinib
Participants who received 2 mg Baricitinib at Period 1 continued to receive 2 mg Baricitinib dose administered orally QD in Period 2.
Drug: Baricitinib
Participants who received 2 mg Baricitinib at Period 1 switched to receive 4 mg Baricitinib dose administered orally QD in Period 2.
Drug: Baricitinib
Participants who received 2 mg Baricitinib at Period 1 switched to receive Placebo administered orally QD in Period 2.
Drug: Placebo
Participants who received 4 mg Baricitinib at Period 1 switched to receive Placebo administered orally QD in Period 2.
Drug: Placebo
Participants who received 4 mg Baricitinib at Period 1 continued to receive 4 mg Baricitinib administered orally QD in Period 2.
Drug: Baricitinib
Participants who received one 4 mg Baricitinib tablet administered orally QD.
Drug: Baricitinib
Administered orally.
Also known as: LY3009104
Administered orally.
Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 - Phase 3
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.
Time frame: Week 36
Percent Change From Baseline in SALT Score - Phase 3 Open-Label Addendum
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100, with lower score indicating better health outcomes.
Time frame: Baseline, Week 52
Percent Change From Baseline in SALT Score - Phase 3
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100, with lower score indicating better health outcomes. Least Squares Mean (LSM) was calculated using analysis of covariance (ANCOVA) with geographic region duration of current episode at baseline (\< 4 years versus ≥4 years), treatment group, and baseline value in the model.
Time frame: Baseline, Week 36
Percentage of Participants Achieving 50% Improvement of SALT (SALT50) - Phase 3
SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process . The SALT score will range from 0% to 100%. with lower score indicating better health outcomes.
Time frame: Week 12
Time for Participants to Achieve SALT ≤ 20 at Week 36 - Phase 3
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Kaplan-Meier method was used for analysis. Time for participants to achieve salt ≤ 20 at week 36 were reported in this outcome measure.
Time frame: Week 36
Percentage of Participants Achieving Clinician Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3
ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.
Time frame: Week 36
Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3
ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.
Time frame: Week 36
Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3
PRO is an assessment of the participant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).
Time frame: Week 36
Percentage of Participants Achieving PRO Measure for EB 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥ 2 at Baseline) - Phase 3
PRO is an assessment of the participant's current appearance of eyebrows. It is comprised of 4 category response options: 0 = I have full EB on each eye; 1= I have a minimal gap(s) or a minimal amount of thinning in at least 1 of my EB; 2 = I have a large gap(s) or a large amount of thinning in at least 1 of my EB; and 3 = I have no or barely any EB hairs.
Time frame: Week 36
Percentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline) - Phase 3
PRO assessment of the participant's current appearance of EL. It is comprised of 4 category response options: 0 = I have full EL on each eyelid; 1 = I have a minimal gap or minimal gaps along the eyelids; 2 = I have a large gap or large gaps along the eyelids; and 3 = I have no or barely any EL hair.
Time frame: Week 36
Mean Change From Baseline in Hospital Anxiety Depression Scale (HADS) Anxiety Score - Phase 3
The Hospital Anxiety Depression Scale (HADS) is a 14 item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (e.g., 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression. LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.
Time frame: Baseline, Week 36
Mean Change From Baseline in HADS Depression Score - Phase 3
The HADS is a 14 item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (e.g., 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression. LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.
Time frame: Baseline, Week 36
Percentage of Participants Achieving SALT ≤ 20 - Phase 3 Open-Label Addendum
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.
Time frame: Week 52
Percentage of Participants Achieving 50% Improvement of SALT (SALT50) - Phase 3 Open-Label Addendum
SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process . The SALT score will range from 0% to 100%. with lower score indicating better health outcomes.
Time frame: Week 52
Percentage of Participants Achieving ClinRO Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum
ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.
Time frame: Week 52
Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum
ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.
Time frame: Week 52
Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3 Open-Label Addendum
PRO is an assessment of the participant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).
Time frame: Week 52
The study was conducted in three separate parts with no participant overlap: • Phase 2 (Weeks 0-200): Participants completed 12 weeks of treatment or early discontinuation. At Week 12, an interim analysis was conducted to determine doses for Phase 3. Based on these Phase 2 interim results, subsequent participants in Phase 3 were enrolled and assigned to receive either baricitinib 2 mg or 4 mg.
| Milestone | Placebo Phase 2 | 1 Milligram (mg) / 4 mg Baricitinib Phase 2 | 2 mg Baricitinib Phase 2 | 4 mg Baricitinib Phase 2 | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 | Placebo/ Placebo Phase 3 | Placebo/ 2 mg Baricitinib Phase 3 | Placebo/ 4 mg Baricitinib Phase 3 | 2 mg Baricitinib /2 mg Baricitinib Phase 3 | 2 mg Baricitinib /4 mg Baricitinib Phase 3 | 2 mg Baricitinib / Placebo Phase 3 | 4 mg Baricitinib / Placebo Phase 3 | 4 mg Baricitinib /4 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 Open-Label Addendum |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 28 | 28 | 27 | 27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Safety population | 28 | 28 | 27 | 27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| All baricitinib phase 2 (combined baricitinib: 1 mg/4 mg, 2 mg and 4 mg) -safety population | 24 | 28 | 27 | 27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 10 | 11 | 15 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 18 | 17 | 12 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 6 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 5 | 6 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol defined discontinuation criteria met at week 76 | 7 | 4 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Did not meet study criteria; out of range labs | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Site procedural error; participant initiated commercial treatment | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo Phase 2 | 1 Milligram (mg) / 4 mg Baricitinib Phase 2 | 2 mg Baricitinib Phase 2 | 4 mg Baricitinib Phase 2 | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 | Placebo/ Placebo Phase 3 | Placebo/ 2 mg Baricitinib Phase 3 | Placebo/ 4 mg Baricitinib Phase 3 | 2 mg Baricitinib /2 mg Baricitinib Phase 3 | 2 mg Baricitinib /4 mg Baricitinib Phase 3 | 2 mg Baricitinib / Placebo Phase 3 | 4 mg Baricitinib / Placebo Phase 3 | 4 mg Baricitinib /4 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 Open-Label Addendum |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 189 | 184 | 281 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Safety population | 0 | 0 | 0 | 0 | 189 | 183 | 280 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| All baricitinib phase 3 (combined baricitinib: 2 mg and 4 mg) - safety population | 0 | 0 | 0 | 0 | 156 | 183 | 280 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 159 | 163 | 252 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 30 | 21 | 29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 6 | 7 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Due to pandemic | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 17 | 10 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized, not treated | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of adherence | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliant with protocol | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant relocated and could not come to site visits | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo Phase 2 | 1 Milligram (mg) / 4 mg Baricitinib Phase 2 | 2 mg Baricitinib Phase 2 | 4 mg Baricitinib Phase 2 | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 | Placebo/ Placebo Phase 3 | Placebo/ 2 mg Baricitinib Phase 3 | Placebo/ 4 mg Baricitinib Phase 3 | 2 mg Baricitinib /2 mg Baricitinib Phase 3 | 2 mg Baricitinib /4 mg Baricitinib Phase 3 | 2 mg Baricitinib / Placebo Phase 3 | 4 mg Baricitinib / Placebo Phase 3 | 4 mg Baricitinib /4 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 Open-Label Addendum |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 76 | 73 | 32 | 121 | 10 | 109 | 143 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 27 | 37 | 20 | 60 | 7 | 29 | 96 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 49 | 36 | 12 | 61 | 3 | 80 | 47 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 2 | 0 | 0 | 1 | 4 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 4 | 2 | 4 | 0 | 8 | 5 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 3 | 1 | 9 | 2 | 8 | 12 | 0 |
| Withdrew: Protocol defined discontinuation criteria met at week 76 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 19 | 0 | 36 | 0 | 51 | 4 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 9 | 6 | 3 | 11 | 0 | 11 | 19 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Due to pandemic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Site closed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Due to time constraints and inability to attend required study visits | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Met exclusion criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Placebo Phase 2 | 1 Milligram (mg) / 4 mg Baricitinib Phase 2 | 2 mg Baricitinib Phase 2 | 4 mg Baricitinib Phase 2 | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 | Placebo/ Placebo Phase 3 | Placebo/ 2 mg Baricitinib Phase 3 | Placebo/ 4 mg Baricitinib Phase 3 | 2 mg Baricitinib /2 mg Baricitinib Phase 3 | 2 mg Baricitinib /4 mg Baricitinib Phase 3 | 2 mg Baricitinib / Placebo Phase 3 | 4 mg Baricitinib / Placebo Phase 3 | 4 mg Baricitinib /4 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 Open-Label Addendum |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 |
| Safety population | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Randomized but not treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.
| percentage of participants | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 |
|---|---|---|---|
| Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 - Phase 3 | 5.3 (2.9 to 9.5) | 21.7 (16.4 to 28.2) | 35.2 (29.9 to 41.0) |
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100, with lower score indicating better health outcomes.
| percent change | 4 mg Baricitinib Phase 3 Open-Label Addendum |
|---|---|
| Percent Change From Baseline in SALT Score - Phase 3 Open-Label Addendum | -40.44 ± 33.182 |
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100, with lower score indicating better health outcomes. Least Squares Mean (LSM) was calculated using analysis of covariance (ANCOVA) with geographic region duration of current episode at baseline (\< 4 years versus ≥4 years), treatment group, and baseline value in the model.
| percent change | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 |
|---|---|---|---|
| Percent Change From Baseline in SALT Score - Phase 3 | -8.13 ± 3.100 | -31.23 ± 3.157 | -45.79 ± 2.663 |
SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process . The SALT score will range from 0% to 100%. with lower score indicating better health outcomes.
| percentage of participants | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 |
|---|---|---|---|
| Percentage of Participants Achieving 50% Improvement of SALT (SALT50) - Phase 3 | 4.8 (2.5 to 8.8) | 9.8 (6.3 to 14.9) | 21.7 (17.3 to 26.9) |
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Kaplan-Meier method was used for analysis. Time for participants to achieve salt ≤ 20 at week 36 were reported in this outcome measure.
| Days | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 |
|---|---|---|---|
| Time for Participants to Achieve SALT ≤ 20 at Week 36 - Phase 3 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.
| percentage of participants | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 |
|---|---|---|---|
| Percentage of Participants Achieving Clinician Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3 | 3.2 (1.3 to 8.0) | 19.1 (13.4 to 26.5) | 31.4 (25.2 to 38.3) |
ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.
| percentage of participants | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 |
|---|---|---|---|
| Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3 | 3.1 (1.1 to 8.8) | 13.5 (8.4 to 21.1) | 33.5 (26.8 to 41.0) |
PRO is an assessment of the participant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).
| percentage of participants | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 |
|---|---|---|---|
| Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3 | 5.0 (2.6 to 9.2) | 16.0 (11.3 to 22.2) | 33.1 (27.8 to 38.9) |
PRO is an assessment of the participant's current appearance of eyebrows. It is comprised of 4 category response options: 0 = I have full EB on each eye; 1= I have a minimal gap(s) or a minimal amount of thinning in at least 1 of my EB; 2 = I have a large gap(s) or a large amount of thinning in at least 1 of my EB; and 3 = I have no or barely any EB hairs.
| percentage of participants | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 |
|---|---|---|---|
| Percentage of Participants Achieving PRO Measure for EB 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥ 2 at Baseline) - Phase 3 | 3.1 (1.2 to 7.6) | 16.3 (11.1 to 23.3) | 32.1 (25.7 to 39.1) |
PRO assessment of the participant's current appearance of EL. It is comprised of 4 category response options: 0 = I have full EL on each eyelid; 1 = I have a minimal gap or minimal gaps along the eyelids; 2 = I have a large gap or large gaps along the eyelids; and 3 = I have no or barely any EL hair.
| percentage of participants | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 |
|---|---|---|---|
| Percentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline) - Phase 3 | 2.0 (0.6 to 7.0) | 19.6 (13.3 to 28.0) | 29.8 (23.3 to 37.3) |
The Hospital Anxiety Depression Scale (HADS) is a 14 item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (e.g., 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression. LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.
| score on a scale | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 |
|---|---|---|---|
| Mean Change From Baseline in Hospital Anxiety Depression Scale (HADS) Anxiety Score - Phase 3 | -0.40 ± 0.234 | -1.22 ± 0.236 | -0.93 ± 0.199 |
The HADS is a 14 item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (e.g., 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression. LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.
| score on a scale | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 |
|---|---|---|---|
| Mean Change From Baseline in HADS Depression Score - Phase 3 | 0.04 ± 0.210 | -0.38 ± 0.213 | -0.28 ± 0.179 |
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.
| percentage of participants | 4 mg Baricitinib Phase 3 Open-Label Addendum |
|---|---|
| Percentage of Participants Achieving SALT ≤ 20 - Phase 3 Open-Label Addendum | 18.2 (5.1 to 47.7) |
SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process . The SALT score will range from 0% to 100%. with lower score indicating better health outcomes.
| percentage of participants | 4 mg Baricitinib Phase 3 Open-Label Addendum |
|---|---|
| Percentage of Participants Achieving 50% Improvement of SALT (SALT50) - Phase 3 Open-Label Addendum | 45.5 (21.3 to 72.0) |
ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.
| percentage of participants | 4 mg Baricitinib Phase 3 Open-Label Addendum |
|---|---|
| Percentage of Participants Achieving ClinRO Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum | 50.0 (15.0 to 85.0) |
ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.
| percentage of participants | 4 mg Baricitinib Phase 3 Open-Label Addendum |
|---|---|
| Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum | 66.7 (20.8 to 93.9) |
PRO is an assessment of the participant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).
| percentage of participants | 4 mg Baricitinib Phase 3 Open-Label Addendum |
|---|---|
| Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3 Open-Label Addendum | 20.0 (5.7 to 51.0) |
Collected over Phase 2: Baseline up to Week 204 ; Phase 3: Baseline up to Week 252 ; Phase 3 Open-Label addendum : Baseline up to Week 56. (AE Description: As pre-specified in the SAP, AE were assessed using the "safety population". Given the sequential dose change within the Phase 2 Baricitinib 1 mg/4 mg Arm, it was not appropriate to attribute AEs to a single fixed dose, and therefore AEs were not collected separately. Also AE data were not collected separately for the Phase 3 Period 2 Arms.). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Phase 2 | 0/28 (0%) | 0/28 (0%) | 12/28 (42.9%) |
| 2 mg Baricitinib Phase 2 | 0/27 (0%) | 0/27 (0%) | 21/27 (77.8%) |
| 4 mg Baricitinib Phase 2 | 0/27 (0%) | 2/27 (7.4%) | 19/27 (70.4%) |
| All Baricitinib Phase 2 (Combined Baricitinib: 1 mg/4 mg, 2 mg and 4 mg) | 0/106 (0%) | 3/106 (2.8%) | 79/106 (74.5%) |
| Placebo Phase 3 | 0/189 (0%) | 3/189 (1.6%) | 37/189 (19.6%) |
| 2 mg Baricitinib Phase 3 | 0/183 (0%) | 7/183 (3.8%) | 58/183 (31.7%) |
| 4 mg Baricitinib Phase 3 | 0/280 (0%) | 16/280 (5.7%) | 126/280 (45%) |
| All Baricitinib Phase 3 (Combined Baricitinib: 2 mg and 4 mg) | 0/619 (0%) | 40/619 (6.5%) | 275/619 (44.4%) |
| 4 mg Baricitinib Phase 3 Open-Label Addendum | 0/19 (0%) | 1/19 (5.3%) | 13/19 (68.4%) |
| Event | Placebo Phase 2 | 2 mg Baricitinib Phase 2 | 4 mg Baricitinib Phase 2 | All Baricitinib Phase 2 (Combined Baricitinib: 1 mg/4 mg, 2 mg and 4 mg) | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 | All Baricitinib Phase 3 (Combined Baricitinib: 2 mg and 4 mg) | 4 mg Baricitinib Phase 3 Open-Label Addendum |
|---|---|---|---|---|---|---|---|---|---|
| PriapismReproductive system and breast disorders | 0/12 | 0/4 | 0/2 | 0/25 | 0/80 | 0/75 | 0/116 | 0/259 | 1/5 |
| Drug withdrawal syndromeGeneral disorders | 0/28 | 0/27 | 1/27 | 1/106 | 0/189 | 0/183 | 0/280 | 1/619 | 0/19 |
| DiverticulitisInfections and infestations | 0/28 | 0/27 | 1/27 | 1/106 | 0/189 | 0/183 | 0/280 | 0/619 | 0/19 |
| Thermal burnInjury, poisoning and procedural complications | 0/28 | 0/27 | 1/27 | 1/106 | 0/189 | 0/183 | 0/280 | 0/619 | 0/19 |
| Vaginal dysplasiaReproductive system and breast disorders | 0/16 | 0/23 | 0/25 | 1/81 | 0/109 | 0/108 | 0/164 | 0/360 | 0/14 |
| Hand fractureInjury, poisoning and procedural complications | 0/28 | 0/27 | 0/27 | 0/106 | 0/189 | 2/183 | 0/280 | 2/619 | 0/19 |
| Hepatitis acuteHepatobiliary disorders | 0/28 | 0/27 | 0/27 | 0/106 | 0/189 | 0/183 | 2/280 | 2/619 | 0/19 |
| Craniofacial fractureInjury, poisoning and procedural complications | 0/28 | 0/27 | 0/27 | 0/106 | 0/189 | 0/183 | 2/280 | 2/619 | 0/19 |
| Abortion missedPregnancy, puerperium and perinatal conditions | 0/16 | 0/23 | 0/25 | 0/81 | 0/109 | 0/108 | 1/164 | 1/360 | 0/14 |
| Acute myocardial infarctionCardiac disorders | 0/28 | 0/27 | 0/27 | 0/106 | 0/189 | 1/183 | 0/280 | 1/619 | 0/19 |
| Event | Placebo Phase 2 | 2 mg Baricitinib Phase 2 | 4 mg Baricitinib Phase 2 | All Baricitinib Phase 2 (Combined Baricitinib: 1 mg/4 mg, 2 mg and 4 mg) | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 | All Baricitinib Phase 3 (Combined Baricitinib: 2 mg and 4 mg) | 4 mg Baricitinib Phase 3 Open-Label Addendum |
|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/28 | 8/27 | 8/27 | 32/106 | 10/189 | 17/183 | 28/280 | 63/619 | 3/19 |
| AcneSkin and subcutaneous tissue disorders | 0/28 | 2/27 | 3/27 | 8/106 | 1/189 | 13/183 | 19/280 | 49/619 | 4/19 |
| Covid-19Infections and infestations | 0/28 | 0/27 | 2/27 | 15/106 | 3/189 | 18/183 | 46/280 | 130/619 | 2/19 |
| Urinary tract infectionInfections and infestations | 1/28 | 1/27 | 1/27 | 6/106 | 4/189 | 6/183 | 16/280 | 30/619 | 3/19 |
| NasopharyngitisInfections and infestations | 1/28 | 4/27 | 2/27 | 14/106 | 12/189 | 13/183 | 28/280 | 48/619 | 1/19 |
| NeutropeniaBlood and lymphatic system disorders | 0/28 | 2/27 | 3/27 | 7/106 | 0/189 | 0/183 | 0/280 | 0/619 | 2/19 |
| NauseaGastrointestinal disorders | 0/28 | 2/27 | 3/27 | 8/106 | 0/189 | 0/183 | 0/280 | 0/619 | 0/19 |
| Oral herpesInfections and infestations | 1/28 | 3/27 | 1/27 | 6/106 | 0/189 | 0/183 | 0/280 | 0/619 | 1/19 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/28 | 2/27 | 3/27 | 6/106 | 0/189 | 0/183 | 0/280 | 0/619 | 0/19 |
| Back painMusculoskeletal and connective tissue disorders | 3/28 | 3/27 | 1/27 | 4/106 | 0/189 | 0/183 | 0/280 | 0/619 | 0/19 |
All randomized participants from Phase 2, Phase 3, and the Phase 3 open-label addendum.
| Age, Continuous(years) | Placebo Phase 2 | 1 mg Baricitinib Phase 2 | 2 mg Baricitinib Phase 2 | 4 mg Baricitinib Phase 2 | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 Open-Label Addendum | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 40.5 ± 14.23 | 38.6 ± 11.26 | 42.5 ± 13.75 | 42.4 ± 14.91 | 37.4 ± 12.91 | 38.0 ± 12.78 | 36.3 ± 13.27 | 46.0 ± 8.75 | 37.8 ± 13.0 |
| Sex: Female, Male(Participants) | Placebo Phase 2 | 1 mg Baricitinib Phase 2 | 2 mg Baricitinib Phase 2 | 4 mg Baricitinib Phase 2 | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 Open-Label Addendum | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 16 | 18 | 23 | 25 | 109 | 109 | 165 | 15 | 480 |
| Male | 12 | 10 | 4 | 2 | 80 | 75 | 116 | 5 | 304 |
| Race (NIH/OMB)(Participants) | Placebo Phase 2 | 1 mg Baricitinib Phase 2 | 2 mg Baricitinib Phase 2 | 4 mg Baricitinib Phase 2 | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 Open-Label Addendum | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 8 | 5 | 8 | 0 | 22 |
| Asian | 3 | 4 | 3 | 4 | 78 | 76 | 114 | 0 | 282 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 3 |
| Black or African American | 4 | 2 | 3 | 3 | 17 | 7 | 28 | 19 | 83 |
| White | 21 | 22 | 20 | 19 | 83 | 93 | 123 | 0 | 381 |
| More than one race | 0 | 0 | 0 | 0 | 1 | 1 | 6 | 1 | 9 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 4 |
| Region of Enrollment(Participants) | Placebo Phase 2 | 1 mg Baricitinib Phase 2 | 2 mg Baricitinib Phase 2 | 4 mg Baricitinib Phase 2 | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 Open-Label Addendum | Total |
|---|---|---|---|---|---|---|---|---|---|
| South Korea | 0 | 0 | 0 | 0 | 70 | 70 | 107 | 0 | 247 |
| United States | 25 | 25 | 24 | 24 | 103 | 102 | 153 | 20 | 476 |
| Japan | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 12 |
| Mexico | 0 | 0 | 0 | 0 | 16 | 12 | 21 | 0 | 49 |
| Baseline Disease Severity of Alopecia Tool (SALT) Score(units on a scale) | Placebo Phase 2 | 1 mg Baricitinib Phase 2 | 2 mg Baricitinib Phase 2 | 4 mg Baricitinib Phase 2 | Placebo Phase 3 | 2 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 | 4 mg Baricitinib Phase 3 Open-Label Addendum | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 90.0 ± 15.69 | 89.3 ± 17.65 | 86.1 ± 19.32 | 83.4 ± 17.52 | 84.7 ± 17.82 | 86.8 ± 18.01 | 85.3 ± 18.18 | 79.1 ± 21.28 | 85.6 ± 17.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2018 to primary completion in Feb 2021, 28 months.
Results were first posted in Oct 2025, 4 years 7 months after primary completion. A results delay was requested in Feb 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib